Evidence map›Paper›PMID 32474689›Full record

SynthesisEndocrine2020

Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis.

Mei Qiu, Shu-Yan Liu, Jin-Song Gu, Kai-Kai Li, Ling-Lin Li, Liang-Liang Ding

Abstract readLetterMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Endocrine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Mei QiuDepartment of General Medicine, Guangdong Medical University Affiliated Longhua Central Hospital, Shenzhen, China.ORCID http://orcid.org/0000-0001-5013-657X
Shu-Yan LiuDepartment of Endocrinology, Second Affiliated Hospital of Kunming Medical University, Kunming, China.ORCID http://orcid.org/0000-0001-9345-0825
Jin-Song GuDepartment of Cardiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Kai-Kai LiDepartment of General Medicine, The Central Hospital of Tuoshi Town, Tianmen, China.
Ling-Lin LiDepartment of Nephrology, First Affiliated Hospital of Kunming Medical University, Kunming, China.
Liang-Liang DingDepartment of Endocrinology, Guangdong Medical University Affiliated Longhua Central Hospital, Shenzhen, China. 15887847798m0@sina.cn.ORCID http://orcid.org/0000-0003-0374-2539
Guangdong Medical College · CNKunming Medical University · CNNanjing Medical University · CNThe First People's Hospital of Tianmen · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsGlucosidesHumansHypoglycemic AgentsGlucosidesHypoglycemic AgentsSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID32474689
OpenAlexW3028712259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.